KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $7.80 $12.85 Thursday, 25th Apr 2024 OTLK stock ended at $8.19. This is 0.122% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 6.50% from a day low at $7.85 to a day high of $8.36.
90 days $0.309 $12.85
52 weeks $0.200 $12.85

Historical Outlook Therapeutics Inc. prices

Date Open High Low Close Volume
Apr 25, 2024 $8.14 $8.36 $7.85 $8.19 148 757
Apr 24, 2024 $8.29 $8.63 $8.00 $8.20 239 030
Apr 23, 2024 $8.21 $8.44 $8.15 $8.20 151 332
Apr 22, 2024 $8.27 $8.37 $7.80 $8.09 182 640
Apr 19, 2024 $8.28 $8.63 $8.00 $8.17 270 185
Apr 18, 2024 $8.79 $8.84 $8.12 $8.29 233 352
Apr 17, 2024 $8.93 $9.26 $8.53 $8.61 265 175
Apr 16, 2024 $8.54 $9.04 $8.54 $8.75 136 686
Apr 15, 2024 $8.50 $8.79 $8.44 $8.62 233 526
Apr 12, 2024 $9.03 $9.19 $8.61 $8.70 266 356
Apr 11, 2024 $9.09 $9.34 $8.75 $9.04 392 627
Apr 10, 2024 $9.06 $9.15 $8.55 $8.99 442 455
Apr 09, 2024 $9.35 $9.98 $9.03 $9.26 359 646
Apr 08, 2024 $9.23 $9.48 $8.89 $9.35 228 164
Apr 05, 2024 $9.50 $9.61 $9.05 $9.26 195 696
Apr 04, 2024 $9.20 $9.86 $8.74 $9.52 893 827
Apr 03, 2024 $9.78 $10.21 $9.00 $9.12 771 092
Apr 02, 2024 $10.33 $10.86 $8.85 $9.70 1 014 177
Apr 01, 2024 $12.36 $12.85 $10.00 $10.26 1 179 293
Mar 28, 2024 $9.39 $12.70 $9.39 $11.94 1 543 665
Mar 27, 2024 $9.36 $10.55 $8.77 $9.37 1 466 273
Mar 26, 2024 $8.14 $8.97 $8.13 $8.68 410 687
Mar 25, 2024 $8.74 $8.92 $7.70 $8.51 827 619
Mar 22, 2024 $10.77 $11.72 $8.31 $8.63 20 963 008
Mar 21, 2024 $6.82 $7.74 $6.80 $7.04 275 136
Click to get the best stock tips daily for free!

About Outlook Therapeutics Inc.

Outlook Therapeutics. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice... OTLK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT